Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV)

References

• Tabor DE, Fernandes F, Langedijk AC, et al. Global molecular epidemiology of respiratory syncytial virus from the 2017-2018 INFORM-RSV study. J Clin Microbiol. 2020;59(1). DOI:https://doi.org/10.1128/JCM.01828-20.
   Google Scholar
• Stein RT, Bont LJ, Zar H, et al. Respiratory syncytial virus hospitalization and mortality: systematic review and meta-analysis. Pediatr Pulmonol. 2017;52(4):556–569.
   PubMed Web of Science ®Google Scholar
• Li Y, Johnson EK, Shi T, et al. National burden estimates of hospitalisations for acute lower respiratory infections due to respiratory syncytial virus in young children in 2019 among 58 countries: a modelling study. Lancet Respir Med. 2021;9(2):175–185.
   PubMed Web of Science ®Google Scholar
• Li X, Willem L, Antillon M, et al. Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries. BMC Med. 2020;18(1):82.
   PubMed Web of Science ®Google Scholar
• Shi T, Denouel A, Tietjen AK, et al. global disease burden estimates of respiratory syncytial virus-associated acute respiratory infection in older adults in 2015: a systematic review and meta-analysis. J Infect Dis. 2020;222(Supplement_7):S577–S583.
   PubMedGoogle Scholar
• Garcia-Garcia ML, Calvo Rey C, Del Rosal Rabes T. Pediatric asthma and viral infection. Arch Bronconeumol. 2016;52(5):269–273.
   PubMed Web of Science ®Google Scholar
• Kalina WV, Gershwin LJ. Progress in defining the role of RSV in allergy and asthma: from clinical observations to animal models. Clin Dev Immunol. 2004;11(2):113–119.
   PubMedGoogle Scholar
• Pangesti KNA, Abd El Ghany M, Walsh MG, et al. Molecular epidemiology of respiratory syncytial virus. Rev Med Virol. 2018;28(2):e1968.
   Web of Science ®Google Scholar
• Kutsaya A, Teros-Jaakkola T, Kakkola L, et al. Prospective clinical and serological follow-up in early childhood reveals a high rate of subclinical RSV infection and a relatively high reinfection rate within the first 3 years of life. Epidemiol Infect. 2016;144(8):1622–1633.
   PubMed Web of Science ®Google Scholar
• Munoz FM. Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy? Curr Opin Infect Dis. 2015;28(3):221–224.
   PubMed Web of Science ®Google Scholar
• Falsey AR, Hennessey PA, Formica MA, et al. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005;352(17):1749–1759.
   PubMed Web of Science ®Google Scholar
• Roberts JN, Graham BS, Karron RA, et al. Challenges and opportunities in RSV vaccine development: meeting report from FDA/NIH workshop. Vaccine. 2016;34(41):4843–4849.
   PubMed Web of Science ®Google Scholar
• Shah JN, Chemaly RF. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood. 2011;117(10):2755–2763.
   PubMed Web of Science ®Google Scholar
• Jorquera PA, Oakley KE, Tripp RA. Advances in and the potential of vaccines for respiratory syncytial virus. Expert Rev Respir Med. 2013;7(4):411–427.
   PubMed Web of Science ®Google Scholar
• Sandritter T. Palivizumab for respiratory syncytial virus prophylaxis. J Pediatr Health Care. 1999;13(4):191–195. quiz 196-197.
   PubMedGoogle Scholar
• Boyoglu-Barnum S, Tripp RA. Up-to-date role of biologics in the management of respiratory syncytial virus. Expert Opin Biol Ther. 2020;20(9):1073–1082.
   PubMed Web of Science ®Google Scholar
• McBride JT, McConnochie KM. RSV, recurrent wheezing, and ribavirin. Pediatr Pulmonol. 1998;25(3):145–146.
   PubMed Web of Science ®Google Scholar
• Bergeron HC, Tripp RA. Emerging small and large molecule therapeutics for respiratory syncytial virus. Expert Opin Investig Drugs. 2020;29(3):285–294.
   PubMed Web of Science ®Google Scholar
• Tripp RA, Power UF, Openshaw PJM, et al. Respiratory syncytial virus: targeting the G protein provides a new approach for an old problem. J Virol. 2018;92(3). DOI:https://doi.org/10.1128/JVI.01302-17
   Google Scholar
• Mazur NI, Higgins D, Nunes MC, et al. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infect Dis. 2018;18(10):e295–e311.
   PubMed Web of Science ®Google Scholar
• Battles MB, McLellan JS. Respiratory syncytial virus entry and how to block it. Nat Rev Microbiol. 2019;17(4):233–245.
   PubMed Web of Science ®Google Scholar
• Borchers AT, Chang C, Gershwin ME, et al. Respiratory syncytial virus–a comprehensive review. Clin Rev Allergy Immunol. 2013;45(3):331–379.
   PubMed Web of Science ®Google Scholar
• McLellan JS, Ray WC, Peeples ME. Structure and function of respiratory syncytial virus surface glycoproteins. Curr Top Microbiol Immunol. 2013;372:83–104.
   PubMed Web of Science ®Google Scholar
• Cane PA. Analysis of linear epitopes recognised by the primary human antibody response to a variable region of the attachment (G) protein of respiratory syncytial virus. J Med Virol. 1997;51(4):297–304.
   PubMed Web of Science ®Google Scholar
• Cane PA, Pringle CR. Evolution of subgroup A respiratory syncytial virus: evidence for progressive accumulation of amino acid changes in the attachment protein. J Virol. 1995;69(5):2918–2925.
   PubMed Web of Science ®Google Scholar
• Feldman SA, Hendry RM, Beeler JA. Identification of a linear heparin binding domain for human respiratory syncytial virus attachment glycoprotein G. J Virol. 1999;73(8):6610–6617.
   PubMed Web of Science ®Google Scholar
• Teng MN, Whitehead SS, Collins PL. Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. Virology. 2001;289(2):283–296.
   PubMed Web of Science ®Google Scholar
• Chirkova T, Lin S, Oomens AGP, et al. CX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells. J Gen Virol. 2015;96(9):2543–2556.
   PubMedGoogle Scholar
• Anderson CS, Chu CY, Wang Q, et al. CX3CR1 as a respiratory syncytial virus receptor in pediatric human lung. Pediatr Res. 2020;87(5):862–867.
   PubMed Web of Science ®Google Scholar
• Johnson SM, McNally BA, Ioannidis I, et al. Respiratory syncytial virus uses CX3CR1 as a receptor on primary human airway epithelial cultures. PLoS Pathog. 2015;11(12):e1005318.
   PubMed Web of Science ®Google Scholar
• Jeong KI, Piepenhagen PA, Kishko M, et al. cx3cr1 is expressed in differentiated human ciliated airway cells and co-localizes with respiratory syncytial virus on cilia in a G protein-dependent manner. PLoS One. 2015;10(6):e0130517.
   PubMed Web of Science ®Google Scholar
• Tripp RA, Dakhama A, Jones LP, et al. The G glycoprotein of respiratory syncytial virus depresses respiratory rates through the CX3C motif and substance P. J Virol. 2003;77(11):6580–6584.
   PubMed Web of Science ®Google Scholar
• Li XQ, Fu ZF, Alvarez R, et al. Respiratory syncytial virus (RSV) infects neuronal cells and processes that innervate the lung by a process involving RSV G protein. J Virol. 2006;80(1):537–540.
   PubMed Web of Science ®Google Scholar
• Haynes LM, Jones LP, Barskey A, et al. Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P. J Virol. 2003;77(18):9831–9844.
   PubMed Web of Science ®Google Scholar
• Chirkova T, Boyoglu-Barnum S, Gaston KA, et al. Respiratory syncytial virus G protein CX3C motif impairs human airway epithelial and immune cell responses. J Virol. 2013;87(24):13466–13479.
   PubMed Web of Science ®Google Scholar
• Hendricks DA, Baradaran K, McIntosh K, et al. Appearance of a soluble form of the G protein of respiratory syncytial virus in fluids of infected cells. J Gen Virol. 1987;68(Pt 6):1705–1714.
   PubMedGoogle Scholar
• Bukreyev A, Yang L, Fricke J, et al. The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes. J Virol. 2008;82(24):12191–12204.
   PubMed Web of Science ®Google Scholar
• Bukreyev A, Yang L, Collins PL. The secreted G protein of human respiratory syncytial virus antagonizes antibody-mediated restriction of replication involving macrophages and complement. J Virol. 2012;86(19):10880–10884.
   PubMed Web of Science ®Google Scholar
• Shingai M, Azuma M, Ebihara T, et al. Soluble G protein of respiratory syncytial virus inhibits toll-like receptor 3/4-mediated IFN-beta induction. Int Immunol. 2008;20(9):1169–1180.
   PubMed Web of Science ®Google Scholar
• Tripp RA, Jones LP, Haynes LM, et al. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol. 2001;2(8):732–738.
   PubMed Web of Science ®Google Scholar
• Harcourt J, Alvarez R, Jones LP, et al. Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+T cell responses. J Immunol. 2006;176(3):1600–1608.
   PubMed Web of Science ®Google Scholar
• Kauvar LM, Harcourt JL, Haynes LM, et al. Therapeutic targeting of respiratory syncytial virus G-protein. Immunotherapy. 2010;2(5):655–661.
   PubMed Web of Science ®Google Scholar
• Bakre AA, Harcourt JL, Haynes LM, et al. The Central Conserved Region (CCR) of Respiratory Syncytial Virus (RSV) G protein modulates host miRNA expression and alters the cellular response to infection. Vaccines (Basel). 2017;5(3):16.
   Web of Science ®Google Scholar
• Choi Y, Mason CS, Jones LP, et al. Antibodies to the central conserved region of respiratory syncytial virus (RSV) G protein block RSV G protein CX3C-CX3CR1 binding and cross-neutralize RSV A and B strains. Viral Immunol. 2012;25(3):193–203.
   PubMed Web of Science ®Google Scholar
• Caidi H, Miao C, Thornburg NJ, et al. Anti-respiratory syncytial virus (RSV) G monoclonal antibodies reduce lung inflammation and viral lung titers when delivered therapeutically in a BALB/c mouse model. Antiviral Res. 2018;154:149–157.
   PubMed Web of Science ®Google Scholar
• Zhang W, Choi Y, Haynes LM, et al. Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice. J Virol. 2010;84(2):1148–1157.
   PubMed Web of Science ®Google Scholar
• Collins PL, Huang YT, Wertz GW. Nucleotide sequence of the gene encoding the fusion (F) glycoprotein of human respiratory syncytial virus. Proc Natl Acad Sci U S A. 1984;81(24):7683–7687.
   PubMed Web of Science ®Google Scholar
• Sun Z, Pan Y, Jiang S, et al. Respiratory syncytial virus entry inhibitors targeting the F protein. Viruses. 2013;5(1):211–225.
   PubMed Web of Science ®Google Scholar
• Mastrangelo P, Chin AA, Tan S, et al. Identification of RSV fusion protein interaction domains on the virus receptor, nucleolin. Viruses. 2021;13(2):261.
   PubMed Web of Science ®Google Scholar
• Tayyari F, Marchant D, Moraes TJ, et al. Identification of nucleolin as a cellular receptor for human respiratory syncytial virus. Nat Med. 2011;17(9):1132–1135.
   PubMed Web of Science ®Google Scholar
• Hicks SN, Chaiwatpongsakorn S, Costello HM, et al. Five residues in the apical loop of the respiratory syncytial virus fusion protein F2 subunit are critical for its fusion activity. J Virol. 2018;92(15). DOI:https://doi.org/10.1128/JVI.00621-18
   Google Scholar
• Zhao X, Singh M, Malashkevich VN, et al. Structural characterization of the human respiratory syncytial virus fusion protein core. Proc Natl Acad Sci U S A. 2000;97(26):14172–14177.
   PubMed Web of Science ®Google Scholar
• McLellan JS, Chen M, Joyce MG, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science. 2013;342(6158):592–598.
   PubMed Web of Science ®Google Scholar
• Taleb SA, Al Thani AA, Al Ansari K, et al. Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches. Eur J Clin Microbiol Infect Dis. 2018;37(10):1817–1827.
   PubMed Web of Science ®Google Scholar
• Gilman MS, Castellanos CA, Chen M, et al. Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors. Sci Immunol. 2016;1(6). DOI:https://doi.org/10.1126/sciimmunol.aaj1879.
   PubMed Web of Science ®Google Scholar
• Hause AM, Henke DM, Avadhanula V, et al. Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B. PLoS One. 2017;12(4):e0175792.
   PubMed Web of Science ®Google Scholar
• Marcandalli J, Fiala B, Ols S, et al. Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus. Cell. 2019;176(6):1420–1431. e1417.
   PubMed Web of Science ®Google Scholar
• Sastry M, Zhang B, Chen M, et al. Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus. PLoS One. 2017;12(10):e0186854.
   PubMed Web of Science ®Google Scholar
• Krarup A, Truan D, Furmanova-Hollenstein P, et al. A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat Commun. 2015;6(1):8143.
   PubMedGoogle Scholar
• Rossey I, McLellan JS, Saelens X, et al. Clinical potential of prefusion RSV F-specific antibodies. Trends Microbiol. 2018;26(3):209–219.
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics Committee on Infectious D, American Academy of Pediatrics Bronchiolitis Guidelines C: Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134(2):415–420.
   PubMed Web of Science ®Google Scholar
• Hall CB, Weinberg GA, Blumkin AK, et al. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics. 2013;132(2):e341–348.
   PubMed Web of Science ®Google Scholar
• Paes B. Respiratory syncytial virus in otherwise healthy prematurely born infants: a forgotten majority. Am J Perinatol. 2018;35(6):541–544.
   PubMed Web of Science ®Google Scholar
• Suresh, Gautham. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The impact-RSV study group. Pediatrics. 1998;102(3):531–537.
   Web of Science ®Google Scholar
• Mochizuki H, Kusuda S, Okada K, et al. Scientific committee for elucidation of infantile A: palivizumab prophylaxis in preterm infants and subsequent recurrent wheezing. Six-year follow-up study. Am J Respir Crit Care Med. 2017;196(1):29–38.
   PubMed Web of Science ®Google Scholar
• Scheltema NM, Nibbelke EE, Pouw J, et al. Respiratory syncytial virus prevention and asthma in healthy preterm infants: a randomised controlled trial. Lancet Respir Med. 2018;6:257–264.
   PubMed Web of Science ®Google Scholar
• Elhassan NO, Sorbero ME, Hall CB, et al. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease. Arch Pediatr Adolesc Med. 2006;160(10):1070–1076.
   PubMedGoogle Scholar
• La Fleur P, Argaez C. In palivizumab for infection prevention in inuit infants: a review of the clinical effectiveness and cost-effectiveness. 2019. Edited by. CADTH Rapid Response Reports
   Google Scholar
• Hussman JM, Li A, Paes B, et al. A review of cost-effectiveness of palivizumab for respiratory syncytial virus. Expert Rev Pharmacoecon Outcomes Res. 2012;12(5):553–567.
   PubMed Web of Science ®Google Scholar
• Smart KA, Lanctot KL, Paes BA. The cost effectiveness of palivizumab: a systematic review of the evidence. J Med Econ. 2010;13(3):453–463.
   PubMedGoogle Scholar
• Hernandez-Gago Y, Lombardero-Pin M, Ortega de La Cruz C, et al. Cost effectiveness of a protocol using palivizumab in preterm infants. Farm Hosp. 2017;41(2):169–186.
   PubMed Web of Science ®Google Scholar
• Ramilo O, Lagos R, Saez-Llorens X, et al. Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness. Pediatr Infect Dis J. 2014;33(7):703–709.
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibodies to watch in 2016. MAbs. 2016;8(2):197–204.
   PubMed Web of Science ®Google Scholar
• Simoes EAF, Forleo-Neto E, Geba GP, et al. Suptavumab for the prevention of medically attended respiratory syncytial virus infection in preterm infants. Clin Infect Dis. 2020;73(11):e4400–e4408.
   Web of Science ®Google Scholar
• Zhu Q, McLellan JS, Kallewaard NL, et al. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Sci Transl Med. 2017;9(388). DOI:https://doi.org/10.1126/scitranslmed.aaj1928.
   Google Scholar
• McLellan JS, Chen M, Leung S, et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science. 2013;340(6136):1113–1117.
   PubMed Web of Science ®Google Scholar
• Phung E, Chang LA, Morabito KM, et al. Epitope-specific serological assays for RSV: conformation matters. Vaccines (Basel). 2019;7(1):23.
   Web of Science ®Google Scholar
• Kwakkenbos MJ, Diehl SA, Yasuda E, et al. Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nat Med. 2010;16(1):123–128.
   PubMed Web of Science ®Google Scholar
• Dall’Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem. 2006;281(33):23514–23524.
   PubMed Web of Science ®Google Scholar
• Saunders KO. Conceptual approaches to modulating antibody effector functions and circulation half-life. Front Immunol. 2019;10:1296.
   PubMed Web of Science ®Google Scholar
• Griffin MP, Khan AA, Esser MT, et al. Safety, tolerability, and pharmacokinetics of MEDI8897, the respiratory syncytial virus prefusion F-targeting monoclonal antibody with an extended half-life, in healthy adults. Antimicrob Agents Chemother. 2017;61(3). DOI:https://doi.org/10.1128/AAC.01714-16
   Web of Science ®Google Scholar
• Domachowske JB, Khan AA, Esser MT, et al. Safety, tolerability and pharmacokinetics of MEDI8897, an extended half-life single-dose respiratory syncytial virus prefusion F-targeting monoclonal antibody administered as a single dose to healthy preterm infants. Pediatr Infect Dis J. 2018;37:886–892.
   PubMed Web of Science ®Google Scholar
• Griffin MP, Yuan Y, Takas T, et al. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 2020;383(5):415–425.
   PubMed Web of Science ®Google Scholar
• Kemp A. US FDA grants breakthrough therapy designation for potential next-generation RSV medicine MEDI8897. Edited by. 2019. Accessed21 October 2021. https://www.astrazeneca.com/media-centre/press-releases/2019/us-fda-grants-breakthrough-therapy-designation-for-potential-next-generation-RSV-medicine-medi8897.html#!
   Google Scholar
• Sanofi: Nirsevimab shows positive topline results in RSV Phase 2/3 MEDLEY trial. Edited by. 2021. Accessed21 October 2021. https://www.sanofi.com/en/media-room/press-releases/2021/2021-06-28-08-00-00-2253567
   Google Scholar
• Sanofi: Nirsevimab demonstrated protection against respiratory syncytial virus disease. in healthy infants in Phase 3 trial 2021.
   Google Scholar
• Lin GL, Drysdale SB, Snape MD, et al. Distinct patterns of within-host virus populations between two subgroups of human respiratory syncytial virus. Nat Commun. 2021;12(1):5125.
   PubMed Web of Science ®Google Scholar